First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

• Status: Terminated
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II clinical trial measuring the effectiveness of the combination of Capecitabine and cetuximab for first line treatment of colorectal cancer in elderly patients and/or those with multiple comorbidities unable to receive standard chemotherapy. This study will be open approximately 2-3 years. Approximately 36 patients will be enrolled on this study. The study will begin enrolling at The Cancer Institute of New Jersey, with 17 patients in the first group. If more than 4 responses are noted, the accrual will continue to 36 patients throughout CINJOG.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Medicine and Dentistry of New Jersey
• Collaborators: Bristol-Myers Squibb; Rutgers Cancer Institute of New Jersey
• Treatments: Capecitabine; Cetuximab

Criteria

Inclusion Criteria

• Histologically or cytologically proven diagnosis of locally extensive or metastatic colorectal cancer, not amenable to curative therapy.

• No prior therapy for metastatic disease. Only 5-fluorouracil and leucovorin chemotherapy in the adjuvant setting will be allowed and the last treatment was given more then 6 months prior to metastatic disease development.

• Patients with an ECOG performance score of 2 AND/OR Charlson comorbidity index of ³ 4.

• Patients must be documented by the physician to be medically unable to tolerate oxaliplatin and/or irinotecan based chemotherapy.

• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ³ 20 mm with conventional techniques or as ³10 mm with spiral CT scan.

• Life expectancy of greater than 3 months.

• Laboratory values showing adequate organ function prior to going on-study:

• Absolute neutrophil count (ANC) ≥ 2.5 x 109/L

• Platelets (PLT) 100 x 109/L

• Hemoglobin 9g/dl (with or without transfusion)

• Metabolic:Calculated creatinine clearance > 50 ml/min

• Total Bilirubin £ 1.5 x Upper limit of normal (ULN)

• AST £ 3 x ULN

• Patient should be able to ingest oral medication.

• Ability to understand and sign an approved informed consent.

Exclusion Criteria

• Patients with uncontrolled systemic disease other than the patient's colorectal cancer (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) for which the patient was admitted to the hospital within the prior month. Patients with stable respiratory, cardiac, hepatic or renal disease may participate subject to the guidelines in the eligibility criteria above.

• Presence of dementia or delirium.

• Unable to eat, dress, bathe or use the toilet independently. The patient must be able to ambulate independently unless limited by arthritis or musculoskeletal condition.

• Patients with active gastritis within the last 3 months prior to study entry.

• No synchronous or prior malignancy other than non-melanomatous skin cancer or insitu carcinoma of the cervix, unless disease free > 3 years.

• Known dihydropyrimidine dehydrogenase (DPD) deficiency.

• Pregnant women are ineligible as treatment involves unforeseeable risks to the participant and to the embryo or fetus. Women must either be not of child bearing potential or have a negative pregnancy test within 7 days of treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Men and women must be willing to use adequate birth control measures to prevent contraception.

• Inability to or unwillingness to comply with protocol defined treatment and assessments.

• Prior therapy that specifically and directly targets the EGFR pathway.

• Prior severe infusion reaction to a monoclonal antibody.

• Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).

• Patients ingesting herbal supplements, botanicals or vitamins in excess of recommended daily dose must be willing to stop their use, 1 week prior to study entry.